Oxurion

Oxurion EBITDA per Share

The EBITDA per Share of Oxurion (OXUR.BR) as of Oct 18, 2026 is 0.16 EUR. In the previous year, EBITDA per Share was -70.91 EUR — a change of -100.23% (higher).

EBITDA per Share

0.16EUR

YoY

-100.23%

Last updated:

EBITDA per Share of Oxurion is 2024 0.16 EUR. EBITDA per Share of Oxurion was 2023 -70.91 EUR. It decreases by -100.23% higher compared to the previous year.

The Oxurion EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2017
0.74 EUR
Jan 1, 2018
-0.93 EUR
Jan 1, 2019
-0.82 EUR
Jan 1, 2020
-0.70 EUR
Jan 1, 2021
-7,023.95 EUR
Jan 1, 2022
-2,540.12 EUR
Jan 1, 2023
-70.91 EUR
Jan 1, 2024
0.16 EUR
The Oxurion EBITDA per Share history
YEAREBITDA per ShareYoY
0.16EUR-100.23%
-70.91EUR-97.21%
-2,540.12EUR-63.84%
-7,023.95EUR+1.01 M%
-0.70EUR-15.37%
-0.82EUR-11.41%
-0.93EUR-225.76%
0.74EUR-200.57%
-0.74EUR-14.10%
-0.86EUR-30.64%
-1.24EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxurion stock

EBITDA per Share of Oxurion is 0.16 EUR in 2024.

EBITDA per Share of Oxurion changed from -70.91 EUR to 0.16 EUR, representing a -100.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Oxurion since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oxurion

All Key Metrics — Oxurion